OTSUKA PHARMACEUTICAL CO., LTD.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public, Subsidiary
- Established
- 1964-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.otsuka.co.jp
A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease Patients
- First Posted Date
- 2012-06-29
- Last Posted Date
- 2014-03-19
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 130
- Registration Number
- NCT01631812
A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients
- First Posted Date
- 2012-06-27
- Last Posted Date
- 2014-03-19
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 143
- Registration Number
- NCT01628965
A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients
- First Posted Date
- 2012-06-27
- Last Posted Date
- 2014-03-19
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 174
- Registration Number
- NCT01628848
A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-06-27
- Last Posted Date
- 2014-05-23
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 420
- Registration Number
- NCT01628926
A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder
- First Posted Date
- 2012-06-12
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 86
- Registration Number
- NCT01617460
A Short Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-06-12
- Last Posted Date
- 2017-04-11
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 92
- Registration Number
- NCT01617447
A Long-Term Extension Trial From Late Phase II of SPM 962 in Patients With Restless Legs Syndrome
- First Posted Date
- 2012-03-26
- Last Posted Date
- 2014-04-23
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 185
- Registration Number
- NCT01562743
Exploratory Study of OPC-12759 Ophthalmic Suspension
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-12-15
- Last Posted Date
- 2015-03-10
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 102
- Registration Number
- NCT01493180
- Locations
- 🇯🇵
Kansai Region, Kobe, Japan
🇯🇵Chugoku region, Kure, Japan
🇯🇵Tokai region, Nagoya, Japan
Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001)
- First Posted Date
- 2011-11-21
- Last Posted Date
- 2021-03-02
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT01475370
- Locations
- 🇯🇵
National Cancer Center, Tokyo, Japan
Safety Study of OPC-12759 Ophthalmic Solution
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-11-11
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT01471093
- Locations
- 🇯🇵
Kansai region, Osaka, Japan
© Copyright 2024. All Rights Reserved by MedPath